logo-loader
RNS
Syncona Limited

Syncona Limited - First Quarter Update

RNS Number : 4754P
Syncona Limited
06 August 2026
 

06 August 2026

 

Syncona Limited

 

("Syncona" or "the Company")

 

First Quarter Update

 

SIML team working closely with portfolio companies to deliver upcoming key value inflection points

 

Syncona Ltd, a leading life science investor, today issues its quarterly update covering the period from 31 March 2026 to 30 June 2026.

 

Chris Hollowood, Chief Executive of Syncona Investment Management Limited, said: "It has been a quarter of meaningful progress across the portfolio, including the first patient dosed in Spur's Phase III pivotal trial. We have been pleased to see continued M&A activity and improving financing conditions across the public biotech markets and later-stage private markets, creating a favourable backdrop for our portfolio. With four key value inflection points expected by the end of CY2026, the portfolio is well positioned to deliver significant upside, which could enable the return of £250 million of proceeds to shareholders in due course. We remain focused on unlocking value by guiding our companies to late-stage development."

 

Financial performance; capital deployment focused on late-stage and clinical-stage companies

 

·    Net assets of £1,038.1 million, 170.6p per share (31 March 2026: £1,037.7 million, 170.6p per share); a NAV per share return of 0.0% in the quarter

·    Life Science Portfolio valued at £866.7 million (31 March 2026: £839.4 million), a return of 0.5% in the quarter

·    Capital pool of £171.4 million at 30 June 2026 (31 March 2026: £198.3 million); £24.9 million deployed in the quarter

o  100% of capital invested into late-stage clinical and clinical-stage companies with £24.9 million deployed into Spur Therapeutics (Spur) and Resolution Therapeutics (Resolution)

 

Portfolio companies demonstrating continued progress ahead of upcoming key value inflection points

 

·    86.4% of the Life Science Portfolio in commercial, late-stage and clinical-stage companies; late-stage clinical is where the SIML team believes significant value can be accessed

·    Continued positive clinical progress across the portfolio including:

-  Spur, a gene therapy company, dosed the first patient in GALILEO-3, its Phase III pivotal clinical trial evaluating avigbagene parvec (FLT201), an investigational gene therapy for Gaucher disease type 1

-  This follows the recent publication of data from its Phase I/II trial which highlighted encouraging improvements in skeletal disease, a major and persistent cause of morbidity in Gaucher patients

-  Resolution has noted the publication of positive four-year follow-up data from the University of Edinburgh's MATCH trial of Regenerative Macrophage Therapy in patients with liver cirrhosis; data from this trial further validates and reinforces the SIML team's investment thesis in Resolution

·    Operational progress with leadership team appointments and changes to support continued strategic progress and delivery:

-  Spur announced that CEO, Michael Parini, transitioned to Chair of its Board of Directors and Chief Scientific Officer, Henning Stennicke, PhD, assumed the role of Chief Operating Officer, bringing deep industry knowledge to his responsibility for operational leadership, whilst Michael will continue to guide the company strategy and provide counsel on ongoing business development priorities

-  Chris Hollowood, who was Chair of Spur, will remain on the Board as a Director, bringing a wealth of expertise in the gene therapy space and important continuity, whilst Dr. Samantha Roberts, Executive Partner at SIML and ex CEO of NICE, will join the Spur Board as a Director

-  Anaveon strengthened its leadership team with the appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer to accelerate Anaveon's clinical development and pipeline expansion

-  Post period end, Mosaic Therapeutics (Mosaic) has appointed Dr. Allison Jeynes as Chair of its Board; Allison brings three decades of drug development and Board and executive leadership experience to guide the company's next phase of growth

 

Four key value inflection points expected in CY2026 with a further four key value inflection points expected before the end of CY2028

 

·    A key value inflection point (KVIP) is a material de-risking event for a portfolio company that has the potential to drive significant NAV growth for Syncona, for example by increasing the possibility of a realisation event, such as M&A activity

·    Syncona is funded to deliver all KVIPs across its portfolio, which have the potential to drive significant NAV growth through M&A and liquidity events

·    Four KVIPs expected by the end of CY2026, including:

o  Data readout from Beacon Therapeutics' Phase II/III pivotal trial in XLRP, which, if positive, will underpin a Biologics License Application (BLA) filing

o  Phase IIb data from iOnctura's lead candidate in metastatic uveal melanoma

o  Further commercial traction following US launch of AUCATZYL® (obe-cel) for Autolus

o  Interim data readout from Resolution's Phase I/II trial in end-stage liver disease 

·    Four capital access milestones expected by the end of CY2026

o  Mosaic now plans to initiate its first clinical study for its lead drug combination in CY2027 (previously H2 CY2026) reflecting its new strategic focus

 

Life Science Portfolio valuations[1]

 

 

 

31 Mar 2026

Net investment in the period

Valuation

change

FX movement

30 June  2026

% of Group NAV

Valuation

Basis[2],[3],[4]

Fully diluted owner-ship stake[5]

Focus area


(£m)

(£m)

(£m)

(£m)

(£m)



(%)


Strategic portfolio companies










On the market










Autolus

30.1


4.8

(0.1)

34.8

3.4%

Quoted

9.3%

Cell therapy

Late-stage clinical










Spur

207.5

7.4

1.2

(0.6)

215.5

20.8%

Cost

86.5%

Gene therapy

Beacon

183.1


0.7

(0.4)

183.4

17.7%

PRI

38.4%

Gene therapy

Clinical










Quell

83.4



(0.2)

83.2

8.0%

PRI

33.7%

Cell therapy

Resolution

71.5

17.5



89.0

8.6%

Cost

82.8%

Cell therapy

Purespring

53.4




53.4

5.1%

PRI

37.8%

Gene therapy

Anaveon

38.4



(0.5)

37.9

3.7%

PRI

37.2%

Biologics

iOnctura

26.2



(0.4)

25.8

2.5%

PRI

22.5%

Small molecules

Mosaic

25.5




25.5

2.5%

Cost

58.4%

Small molecules

Pre-clinical










OMass

49.7




49.7

4.8%

PRI

28.9%

Small molecules

Yellowstone

16.5




16.5

1.6%

Cost

60.9%

Biologics

Forcefield

13.0




13.0

1.3%

PRI

73.7%

Biologics

Slingshot

12.0




12.0

1.2%

Cost

100.0%

Accelerator

Kesmalea

9.2




9.2

0.9%

Cost

59.7%

Small molecules

Re-Aim

4.5




4.5

0.4%

Cost

37.8%

Biologics

Portfolio milestone payments










Clade milestone payment

0.8




0.8

0.1%

DCF


Cell therapy

Syncona investments










CRT Pioneer Fund

10.2




10.2

1.0%

Adj Third Party

64.1%

Oncology

Biomodal

2.3




2.3

0.2%

PRI

3.0%

Epigenetics

Century[6]

2.1

(1.9)

(0.2)


0.0

0.0%

Quoted


Cell therapy

Total Life Science Portfolio

839.4

23.0

6.5

(2.2)

866.7

83.5%

 




Capital pool

198.3

(29.7)

2.9

(0.1)

171.4

16.5%

 

 

 

TOTAL

1,037.7

 

 

 

1,038.1

100.0%

 

 

 

 

Strategic portfolio company milestones

 

Specific portfolio company capital access milestones and key value inflection points (which are set out below) are not without risk and their impact will be affected by various factors including the market environment at the time of their delivery.

 

Life science portfolio company 

Next expected capital access milestones  

SIML team view of potential key value inflection points  

On the market 

Autolus  


H2 CY2026  

·      Further commercial traction following US launch of AUCATZYL® (obe-cel) 

Moving towards being on the market 

Beacon  

 

 

H2 CY2026 

·      Data readout from its Phase II/III pivotal VISTA trial in XLRP  

Spur 


H1 CY2028  

·      Completion of the pivotal stage of its Phase III trial in Gaucher disease  

 

Moving towards publishing definitive data 

iOnctura 


H2 CY2026 

·      Data readout from its Phase II trial in uveal melanoma 

  

Resolution 


H2 CY2026 

·      Interim data readout from its Phase I/II trial in end-stage liver disease 

Moving towards publishing emerging efficacy data 

Quell 


H1 CY2027 

·      Data from its Phase I/II CHILL study in rheumatologic autoimmune diseases  

 

Anaveon 

CY2026 

·      Data readout from its Phase I/II trial of ANV600 

 

CY2026 

·      IND filing for its Phase I/II trial in ANV200 


Purespring 


H1 CY2027  

·      Complement biomarker clinical data  

OMass 

CY2026  

·      Initiation of Phase I trial of its MC2 programme 

CY2027 

·      Data from Phase I trial of MC2 programme 

Mosaic 

CY2027

·      Initiation of first clinical study for lead drug combination (updated)

  

 

Yellowstone 

CY2026  

·      Candidate selection for lead programme  


 

 

 

Enquiries

 

Syncona Ltd

 

Annabel Clark

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona

 

Syncona is a leading life science investor focused on transforming patient outcomes by translating frontier science into therapeutic reality. Our investment manager, Syncona Investment Management Limited (SIML), actively manages a maturing portfolio of leading life science companies, which are diversified across development stage, modality and therapeutic area. Syncona is focused on delivering strong risk-adjusted returns to shareholders by building and scaling its portfolio companies to late-stage development, where significant value can be realised. SIML does this by working in close partnership with world-class academic founders and experienced management teams to develop treatments with the potential for transformational patient impact. For more information, please visit www.synconaltd.com. 

 

 

Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of Syncona Limited. These statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. In particular, many companies in the Syncona Limited portfolio are conducting scientific research and clinical trials where the outcome is inherently uncertain and there is significant risk of negative results or adverse events arising. In addition, many companies in the Syncona Limited portfolio have yet to commercialise a product and their ability to do so may be affected by operational, commercial and other risks.

 

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

 



[1] Portfolio valuations reflect Syncona's total interest in a company or investment

[2] Primary input to fair value of equity holding

[3] The basis of valuation is stated to be "Cost", this means the primary input to fair value is capital invested (cost) which is then calibrated in accordance with our Valuation Policy

[4] The basis of valuation is stated to be "PRI", this means the primary input to fair value is price of recent investment which is then calibrated in accordance with our Valuation Policy

[5] Percentage holding reflects Syncona's ownership stake at the point full current commitments are invested

[6] Syncona received shares in Century as part of the agreement to acquire Clade Therapeutics










This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUQELFBQVLXBBQ
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

8 min read